We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Amyloid P Promotes Binding to Plastics

By Biotechdaily staff writers
Posted on 31 Oct 2005
Researchers studying how the body responds to materials used in the manufacture of implanted medical devices have determined that serum amyloid P protein binds to plastic materials and induces adhesion and activation of leukocytes.

Investigators at Washington University (St. More...
Louis, MO, USA) used gel electrophoresis, ion trap mass spectrometry, and other advanced proteomics techniques to study the binding of serum proteins to plastics such as polypropylene, polyethylene terephthalate (PET), or polydimethylsiloxane (PDMS) that are components of implanted medical devices.

They found that incubation of the plastic materials with 5% serum for longer than four hours resulted in binding of unexpectedly high amounts of serum amyloid P protein. Previous work had shown that serum amyloid P was constitutively expressed in humans, functioned as an opsonin (a molecule that acts as a binding enhancer for the process of phagocytosis), and interacted with receptors on leukocytes. In the current study, published in the October 1, 2005, issue of the Journal of Biomedical Materials Research, it was found that serum amyloid P adsorbed to polystyrene, PDMS, and PET under tissue culture conditions and promoted the adhesion of granulocytes and monocytes in the presence of calcium.

"No one had ever observed serum amyloid P on biomedical materials before, because, unless you were specifically looking for them, the technology was not around to easily identify proteins present in such small amounts,” explained senior author Dr. Donald Elbert, assistant professor of biomedical engineering at Washington University. "No one, including us, had ever posed the hypothesis that this protein might be important in the biocompatibility of materials. Our results show the importance of large-scale techniques that emphasize discovery of new knowledge, rather than just hypothesis-testing.”



Related Links:
Washington University

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Clinical Informatics Platform
CLARION™
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.